Group 1 - The core point of the article is that Qingmu Technology (301110.SZ) announced a significant acquisition involving its wholly-owned subsidiary Qingmu PTE.LTD., which will acquire a controlling stake in Vitalis Pharma AS through a cash transaction totaling 300 million Norwegian Krone (approximately 212 million RMB) [1][2] Group 2 - The acquisition includes purchasing 49.0662% of the shares from Norsund and subscribing to 32.9157% of newly issued shares, resulting in Qingmu Singapore holding a total of 65.8314% of Vitalis, thus becoming the controlling shareholder [1] - Vitalis Pharma AS specializes in high-end health nutrition supplements, with brands like Noromega, offering products such as seal oil, fish oil, astaxanthin, and coenzyme Q10 [2] - The purpose of the acquisition is to implement the company's brand incubation and management strategy, enhancing its competitiveness in the health and wellness sector [2] - Post-acquisition, the company will strengthen its capabilities in brand management, product development, production, and supply chain management, while also becoming the general distributor for the Noromega brand in China, which is expected to improve its sustainable profitability [2]

Group 1 - The core point of the news is that Qingmu Technology's subsidiary, Qingmu PTE. LTD., has signed a share purchase and subscription agreement to acquire a 49.0662% stake in Vitalis Pharma AS for 150 million Norwegian Krone (approximately 106 million RMB) and to subscribe for an additional 32.9157% stake for the same amount, resulting in a total ownership of 65.8314% and making it the controlling shareholder of the target company [1][2] Group 2 - The target company specializes in the research, production, and sales of high-end health nutritional supplements, with brands such as Noromega, and its main products include seal oil, fish oil, astaxanthin, and coenzyme Q10 [2] - The purpose of the acquisition is to implement the company's brand incubation and management strategy, enhancing its competitiveness in the health sector [2] - Post-transaction, the company will strengthen its capabilities in brand management, product research and development, production, and supply chain management, and will become the general distributor for the Noromega brand in China, which is expected to improve its sustainable profitability [2]